Loading
Life sciences · Journal article
Molecular Pharmaceutics · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Hepatocellular carcinoma (HCC) treatment is severely limited by the low efficacy and drug resistance of current monotherapies. While nanocarriers for sorafenib (Sor) delivery have been explored, platforms that combine multimodal therapy and elucidate deep-seated anti-tumor mechanisms remain lacking. To address this, we engineered a nanosystem by loading Sor onto an aluminum-based metal−organic framework (Sor@Al-MOF), which combines chemotherapy with the intrinsic bioactivity of the nanocarrier. Sor@Al-MOF nanoparticles exhibited a well-defined lamellar structure, with a zeta potential of 10.10 ± 0.69 mV. Sor@Al-MOF achieved a high drug loading content (56.43% ± 0.36%) and encapsulation efficiency (77.38% ± 4.20%), and exhibited a cumulative release of 65.74 ± 0.55% at pH 5.3 after 72 h. In vitro, Sor@Al-MOF showed potent cytotoxicity against human HCC HepG2 cells (IC50 = 88.40 ± 0.12 μg/mL). In an intrahepatic Walker 256 rat tumor model, Sor@Al-MOF demonstrated enhanced therapeutic efficacy. Integrated metabolomics provided preliminary insights into potential metabolic changes in this model, including changes in choline kinase α (CHKα)-related glycerophospholipid metabolism. This study presents Sor@Al-MOF as a promising combinatorial nanotherapeutic candidate and offers a foundational basis for exploring metabolism-targeting strategies in liver cancer treatment.